VivoSeq
Metabolic & Endocrine

Dyslipidemia

3

Pipeline Programs↗

5

Active Trials↗

14

Companies Involved↗

Dyslipidemia is an early-stage landscape with 3 programs across 14 companies. The most active players are AstraZeneca, Eli Lilly, Merck & Co..

Intelligence

Pipeline Metrics

Competitive Density

28/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

91/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

1 program

Phase 1Eli Lilly logo

Eli Lilly

1 program

Phase 1Merck & Co. logo

Merck & Co.

0 programs

PreclinicalTakeda logo

Takeda

0 programs

PreclinicalGSK logo

GSK

0 programs

PreclinicalK

Kos Pharmaceuticals

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 13

Administration of UI111

Korea United Pharm. Inc.

Administration of UIC202006

Korea United Pharm. Inc.

AZD4954

AstraZeneca

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

53

clinical trials

Completed40 · 75%
Unknown status4 · 8%
Recruiting3 · 6%
Terminated2 · 4%
Withdrawn2 · 4%
Active, not recruiting2 · 4%

Clinical Trials

Trial Activity

53 trials

To Assess With Ezefeno Tab. in Patients With Dyslipidemia and T2DM
Recruiting·KKorea University Anam Hospital·N/A·NCT06293417·3,958 enrolled
The Effects of Xuezhikang and Atorvastatin on Lipid in Patients With Dyslipidemia and Prediabetes
Recruiting·—·Phase 4·NCT06750783·398 enrolled
A Phase I, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4954 Following Single and Multiple Ascending Dose Administration to Healthy Participants With or Without Elevated Lp(a) Levels, and Participants With Dyslipidemia
Recruiting·AstraZeneca logoAstraZeneca·Phase 1·NCT06980428·136 enrolled
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 in Participants With Dyslipidemia
Active, not recruiting·AstraZeneca logoAstraZeneca·Phase 1·NCT06238466·96 enrolled
Evaluation of Dyslipidemia Management After Statin and Ezetimibe Complex Treatment
Active, not recruiting·Daewoong Pharmaceutical Co. LTD. logoDaewoong Pharmaceutical Co. LTD.·N/A·NCT05614765·18,000 enrolled
Compare the Impact of Xuezhikang and Atorvastatin on Glucose Metabolism in Dyslipidemia Patients With Prediabetes
Completed·—·Phase 4·NCT05238012·392 enrolled
Effects of Nateglinide vs Acarbose on Postprandial Glucose Fluctuation, Dyslipidemia, and Inflammatory Factors
Completed·Novartis logoNovartis·Phase 4·NCT00928889·160 enrolled
A Multiple Ascending Dose Study of ETC-1002 in Subjects With Mild Dyslipidemia
Completed·EEsperion Therapeutics, Inc.·Phase 1·NCT01105598·53 enrolled
Study to Test GSK256073 in Patients With Dyslipidemia
Completed·GSK logoGSK·Phase 2·NCT00903617·80 enrolled
A Study of LY3561774 in Participants With Dyslipidemia
Completed·Eli Lilly logoEli Lilly·Phase 1·NCT04644809·74 enrolled
Pharmacokinetics of Rosuvastatin and Atorvastatin in Pediatric Dyslipidemia Patients
Completed·—·Phase 1·NCT02364258·28 enrolled
EDP167 in Healthy Volunteers and Subjects With Mild Dyslipidemia
Completed·EEddingpharm (Zhuhai) Co., Ltd.·Phase 1·NCT07412080·40 enrolled
Fenofibrate in Dyslipidemia and Metformin-Controlled Diabetes
Completed·SSolvay Pharmaceuticals·Phase 2/3·NCT00349128·382 enrolled
TTA in Treatment of Diabetes and Dyslipidemia
Completed·HHaukeland University Hospital·Phase 2·NCT00605787·16 enrolled
Effect of Virgin Coconut Oil (VCO) on Cardiometabolic Parameters in Patients With Dyslipidemia
Completed·—·Phase 4·NCT03906539·150 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)